Biontech SE (($CC:BNTX.CUR)), Biontech Se Sponsored Adr ((BNTX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioNTech SE is currently conducting a clinical study titled A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer. The study aims to assess the efficacy and safety of a combination therapy involving BNT324, a B7-H3 antibody-drug conjugate, and BNT327, a PD-L1 and VEGF bispecific antibody, in patients with advanced lung cancer, including both small cell and non-small cell types.
The study is testing the combination of BNT324 and BNT327, both administered via intravenous infusion. BNT324 is a B7-H3 antibody-drug conjugate, while BNT327 is a bispecific antibody targeting PD-L1 and VEGF, intended to enhance the treatment of advanced lung cancer.
This interventional study is designed with a randomized allocation and a parallel intervention model, focusing on treatment as its primary purpose. The study is open-label, meaning no masking is used, allowing both researchers and participants to know which treatments are being administered.
The study began on May 2, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 10, 2025, indicating ongoing recruitment and progress in the study.
For investors, this study represents a significant step for BioNTech SE in expanding its oncology portfolio. Positive outcomes could enhance the company’s stock performance and investor confidence, especially given the competitive landscape in cancer treatment. Collaborations with DualityBio Inc. and Biotheus Inc. further underscore the strategic importance of this study.
The study is currently ongoing, with further details available on the ClinicalTrials portal.